CEL-SCI Corporation

The past year has marked CEL-SCI's evolution into a cancer immunotherapy development company as we placed more emphasis on our drug Multikine™. We believe that this emphasis is warranted because Multikine has great potential to overcome the problem of tumor tolerance, a major roadblock in the fight against cancer. If we are right and Multikine truly overcomes tumor tolerance, a process by which a person's immune system does not properly fight the tumor, Multikine might be the answer to 100 years of immunology research.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: